These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23342621)

  • 21. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of serum alpha 1-antitrypsin in prostate pathology].
    Morote Robles J; de Torres Mateos JA; Jardí Margalef R; Palou Redorta J; Aymerich Real J; Prats López J; Soler Roselló A
    Actas Urol Esp; 1986; 10(4):239-42. PubMed ID: 2428211
    [No Abstract]   [Full Text] [Related]  

  • 23. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients.
    El-Akawi ZJ; Abu-Awad AM; Sharara AM; Khader Y
    Neuro Endocrinol Lett; 2010; 31(1):113-6. PubMed ID: 20150872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activity of alpha 1-antitrypsin in blood of patients with prostatic tumor].
    Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):89-90. PubMed ID: 8756740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
    Su HW; Li Y; Xu P
    Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia.
    Aydin A; Arsova-Sarafinovska Z; Sayal A; Eken A; Erdem O; Erten K; Ozgök Y; Dimovski A
    Clin Biochem; 2006 Feb; 39(2):176-9. PubMed ID: 16413012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
    Chakrabarti S; Raha K; Bhunia CL; Bhattachary DK
    J Indian Med Assoc; 2001 Nov; 99(11):627-8, 630. PubMed ID: 12022203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
    Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
    Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum cathepsin D and its density in men with prostate cancer as new predictors of disease progression.
    Hara I; Miyake H; Yamanaka K; Hara S; Kamidono S
    Oncol Rep; 2002; 9(6):1379-83. PubMed ID: 12375052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer.
    Bangma CH; Wildhagen MF; Yurdakul G; Schröder FH; Blijenberg BG
    BJU Int; 2004 Apr; 93(6):720-4. PubMed ID: 15049979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
    Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
    Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.